Poloxamer 407 as a general lipase inhibitor: Its implications in lipid metabolism and atheroma formation in C57BL/6 mice

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 12, 2010, Pages 1807-1812

  Johnston, Thomas P ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Atherosclerosis; Cellular adhesion molecules; Lipase; Peroxisome proliferator activated receptor; Poloxamer 407

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENZYME INHIBITOR; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLOXAMER; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; VASCULAR CELL ADHESION MOLECULE 1;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; C57BL 6 MOUSE; CONTROLLED STUDY; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; LIPID METABOLISM; MOUSE; NONHUMAN; POLYMERIZATION; SINGLE DRUG DOSE; VASCULAR ENDOTHELIUM; VIRUS RECOMBINANT;

ANIMALS; ATHEROSCLEROSIS; DYSLIPIDEMIAS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LIPASE; LIPID METABOLISM; LIPOPROTEIN LIPASE; MICE; MICE, INBRED C57BL; PLAQUE, ATHEROSCLEROTIC; POLOXAMER; PPAR ALPHA; PPAR GAMMA; SURFACE-ACTIVE AGENTS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 78149374045     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01138.x     Document Type: Article

References (34)

1. Gordon T et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-714.
2. Castelli WP et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835-2838.
3. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 104: 503-516.
4. Cockerill GW et al. 1995. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 2001; 15: 1987-1994.
5. Calabresi L et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 1997; 238: 61-65.
6. Shih DM et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000; 275: 17 527-17 535.
7. Tward A et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106: 484-490.
8. Xia P et al. High density lipoproteins (HDL) interrupt the sphingosine signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999; 274: 33 143-33 147.
9. Shaul PW, Mineo C. HDL action on the vascular wall: is the answer NO? J Clin Invest 2004; 113: 509-513.
10. Ahmed W et al. High-density lipoprotein hydrolysis by endo-thelial lipase activates PPARα: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. Circ Res 2006; 98: 490-498.
11. Ziouzenkova O et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an anti-inflammatory role for lipoprotein lipase. Proc Natl Acad Sci USA 2003; 100: 2730-2735.
12. Ziouzenkova O et al. Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein. J Biol Chem 2003; 278: 39 874-39 881.
13. Wilson TM et al. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 527-550.
14. Plutzky J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep 2000; 2: 327-335.
15. Chawla A et al. PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci USA 2003; 100: 1268-1273.
16. Marx N et al. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999; 99: 3125-3131.
17. Jackson SM et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999; 19: 2094-2104.
18. Pasceri V et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000; 101: 235-238.
19. Johnston TP et al. Sex does not seem to influence the formation of aortic lesions in the P-407-induced mouse model of hyperlipidemia and atherosclerosis. J Cardiovasc Pharmacol 2002; 39: 404-411.
20. Wout ZGM et al. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection in the rat. J Parenter Sci Technol 1992; 46: 192-200.
21. Leon C et al. Acute P-407 administration to mice causes hypercholesterolemia by inducing cholesterolgenesis and down-regulating low-density lipoprotein receptor expression. Pharm Res 2006; 23: 1597-1607.
22. Johnston TP et al. Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis 1998; 136: 115-123.
23. Johnston TP. The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis: a review of findings to date. J Cardiovasc Pharmacol 2004; 43: 595-606.
24. Ishida BY et al. Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H. J Lipid Res 1991; 32: 559-568.
25. Paigen B et al. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 1985; 57: 65-73.
26. Johnston TP, Palmer WK. Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochem Pharmacol 1993; 46: 1037-1042.
27. Johnston TP, Goldberg IJ. Inhibition of pancreatic lipase by poloxamer 407 may provide an adjunct treatment strategy for weight loss. J Pharm Pharmacol 2006; 58: 1099-1105.
28. Li C et al. Disposition of poloxamer 407 in rats following a single intraperitoneal injection assessed using a simplified colorimetric assay. J Pharm Biomed Anal 1996; 14: 659-665.
29. McCoy MG et al. Characterization of the lipolytic activity of endothelial lipase. J Lipid Res 2002; 43: 921-929.
30. Wasan KM et al. Poloxamer 407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats. J Pharm Pharm Sci 2003; 6: 189-197.
31. Tanaka H et al. Role of endothelial lipase in plasma HDL levels in a murine model of hypertriglyceridemia. J Atheroscler Thromb 2009; 16: 327-338.
32. Johnston TP, Waxman DJ. The induction of atherogenic dyslipidemia in poloxamer 407-treated mice is not mediated through PPARα. J Pharm Pharmacol 2008; 60: 753-759.
33. Johnston TP, Waxman DJ. Circulating free fatty acids are increased independently of PPARγ activity after administration of poloxamer 407 to mice. Can J Physiol Pharmacol 2008; 86: 643-649.
34. Johnston TP. Poloxamer 407 increases soluble adhesion molecules, ICAM-1, VCAM-1, and E-selectin, in C57BL/6 mice. J Pharm Pharmacol 2009; 61: 1681-1688.